Bayer HealthCare to present cancer drug data at ASCO
18 May 2011 00:00 in Pharmaceutical Company Product News
Bayer HealthCare will be publishing clinical data for a number of important new therapies at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO).
During the event next month, the company will unveil data for Alpharadin, its investigational alpha-pharmaceutical that is currently in phase III development to treat castration-resistant prostate cancer that has spread to the bone.
Further data will be presented for the investigational colorectal cancer and gastrointestinal stromal tumour treatment regorafenib.
These are two of the ten compounds that Bayer HealthCare currently has in its oncology portfolio, with study findings for earlier-stage therapies such as the phase II compound BAY 86-9766 also set to be highlighted.
Dr Kemal Malik, head of global development and member of the Bayer HealthCare executive committee, said: "At ASCO, we are presenting research that supports the clinical potential of these compounds, which have been designed to combat the complex nature and pathomechanism of different cancers."
Last month, the Bayer group published its financial report for the first quarter of 2011, underlining a 7.7 percent year-on-year sales increase for the Bayer HealthCare division.
Other news stories from 18/05/2011
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency